Experimental CAR-T therapy takes on stubborn muscle weakness
NCT ID NCT07413835
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study is testing a new drug, HN2302 (a type of in vivo CAR-T therapy), in just 6 people with refractory myasthenia gravis — a condition where standard treatments fail. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it helps with daily activities and muscle strength. Because it is so small and early, the results will only give a first glimpse of whether this approach is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HN2302 (in vivo CAR-T)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-control myasthenia gravis.
- What could go wrong
- This is a very early, tiny trial with only 6 people. It is designed mainly to check safety, not to prove it works. The treatment may not improve symptoms or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.